

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2011-005316-28/ Novartis Protocol ID CBGG492A2214

*A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in migraine prevention*

Trial CBGG492A2214 was cancelled with no patient enrollment and as such, no results will be reported.